Onconetix (NASDAQ:ONCO – Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($1.28) EPS for the quarter, topping the consensus estimate of ($4,505.00) by $4,503.72, FiscalAI reports. Onconetix had a negative net margin of 1,316.28% and a negative return on equity of 101.08%. The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.02 million.
Onconetix Stock Down 1.0%
ONCO stock traded down $0.01 during mid-day trading on Thursday, reaching $0.88. 44,344 shares of the stock traded hands, compared to its average volume of 297,277. Onconetix has a 52 week low of $0.67 and a 52 week high of $209.50. The business has a 50-day moving average of $0.94 and a two-hundred day moving average of $16.72. The firm has a market capitalization of $1.01 million, a PE ratio of 0.08 and a beta of 2.69.
Hedge Funds Weigh In On Onconetix
An institutional investor recently bought a new stake in Onconetix stock. Citadel Advisors LLC bought a new stake in Onconetix, Inc. (NASDAQ:ONCO – Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 15,633 shares of the company’s stock, valued at approximately $49,000. Citadel Advisors LLC owned about 1.00% of Onconetix as of its most recent SEC filing. Hedge funds and other institutional investors own 23.89% of the company’s stock.
Wall Street Analysts Forecast Growth
Get Our Latest Report on Onconetix
About Onconetix
Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc and changed its name to Onconetix, Inc in December 2023. Onconetix, Inc was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
Featured Stories
- Five stocks we like better than Onconetix
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for Onconetix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconetix and related companies with MarketBeat.com's FREE daily email newsletter.
